NKTX vs. NKTR, KMDA, SBTX, ERAS, ADCT, ATAI, MRSN, VSTM, AVIR, and PGEN
Should you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Nektar Therapeutics (NKTR), Kamada (KMDA), Silverback Therapeutics (SBTX), Erasca (ERAS), ADC Therapeutics (ADCT), Atai Life Sciences (ATAI), Mersana Therapeutics (MRSN), Verastem (VSTM), Atea Pharmaceuticals (AVIR), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Nektar Therapeutics (NASDAQ:NKTR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.
Nektar Therapeutics currently has a consensus target price of $3.50, suggesting a potential upside of 99.43%. Nkarta has a consensus target price of $17.83, suggesting a potential upside of 173.10%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Nektar Therapeutics.
Nektar Therapeutics received 579 more outperform votes than Nkarta when rated by MarketBeat users. However, 72.73% of users gave Nkarta an outperform vote while only 70.61% of users gave Nektar Therapeutics an outperform vote.
Nektar Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
Nkarta has lower revenue, but higher earnings than Nektar Therapeutics. Nkarta is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 3.1% of Nektar Therapeutics shares are owned by insiders. Comparatively, 5.6% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Nkarta had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 7 mentions for Nkarta and 5 mentions for Nektar Therapeutics. Nkarta's average media sentiment score of 0.18 beat Nektar Therapeutics' score of 0.11 indicating that Nektar Therapeutics is being referred to more favorably in the media.
Nkarta has a net margin of 0.00% compared to Nkarta's net margin of -195.02%. Nektar Therapeutics' return on equity of -34.13% beat Nkarta's return on equity.
Summary
Nkarta beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Nkarta News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
